226 completed, 65 unknown, 32 terminated, 17 recruiting. 98 Phase 2, 66 Phase 1, 60 Phase 3, 57 Not applicable, 45 Phase 4.
Follow Neovascularization, Pathologic: new trials by email Literature Review of Neovascularization, Pathologic trials Research Report on Neovascularization, Pathologic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-12-24 | 2026-02-05 |
| Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety Eyelid Speculum Retraction, Cotton-Tipped Applicator Retraction - Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema | Not applicable | Active not recruiting | Jakkrit Juhong | 129 | 2026-09-09 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD) | Phase 2 | Not yet recruiting | Everest Medicines (China) Co.,Ltd. | 244 | 2026-09-01 | 2026-09-10 |
| Artificial Intelligence-Assisted Lesion-Based Urgent Referral Triage of Ultra-Widefield Retinal Images AI-Assisted UWF Lesion-Based Triage System, Unassisted Interpretation - Vision-Threatening Retinal Lesions, Urgent Referral Retinal Findings | Not applicable | Completed | Xiamen Ophthalmology Center Affiliated to Xiamen University | 11 | 2026-07-01 | 2026-09-22 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization Fine-needle diathermy, Bevacizumab - Corneal Neovascularisation | Not applicable | Recruiting | HoChiMinh City Eye Hospital | 51 | 2026-04-01 | 2026-06-11 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
| Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-03-01 | 2026-03-10 |
| Theravex Oral and Theravex Tissue Care Plus in the Healing Process of Mucogingival Surgery Modified Free Gingival Graft (M-FGG), Theravex Bioactive Solutions (Tissue Care Plus and Oral) - Gingival Recession, Localized | Not applicable | Recruiting | Universidad Complutense de Madrid | 30 | 2026-02-17 | 2026-02-24 |
| A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) Aflibercept Intravitreous Injection - Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD) | Phase 4 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 174 | 2026-01-01 | 2026-01-26 |
| Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma 82-Rb injection - Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2026-01-01 | 2026-01-16 |
| Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization. Intrastromal anti-VEGF injection and topical antiviral eye drops, Conventional antiviral topical ocular drops. - Herpes Simplex Keratitis, Corneal Neovascularization | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2025-10-01 | 2026-01-09 |
| Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization Intravitreal faricimab injection - Age-related Macular Degeneration (ARMD), Choroidal Neovascularization | Phase 4 | Not yet recruiting | Kim's Eye Hospital | 30 | 2025-09-23 | 2025-09-23 |
| Urethral Vascularization and Urodynamics 3D Ultrasound - Stress Urinary Incontinence, Ultrasound | Not applicable | Enrolling by invitation | Insel Gruppe AG, University Hospital Bern | 70 | 2025-09-01 | 2026-05-19 |
| Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration Choroidal Neovascularization | Phase 4 | Recruiting | Hospital Authority, Hong Kong | 40 | 2025-08-21 | 2025-10-01 |
| Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO) Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy | Phase 4 | Recruiting | Association for Innovation and Biomedical Research on Light and Image | 120 | 2025-08-06 | 2026-02-06 |
| AVIGA3 (Cohort 2.0) Amsler Grid, AVIGA - Maculopathy | Not applicable | Recruiting | Tan Tock Seng Hospital | 60 | 2025-06-16 | 2026-06-24 |
| The Treatment Burden of Myopic Choroidal Neovascularization anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization - Myopic Choroidal Neovascularisation, Anti-VEGF Treatment | Not yet recruiting | Policlinico Gaspare Rodolico - San Marco Catania | 100 | 2025-06-01 | 2025-06-06 | |
| Effect of Video Viewing on Intravitreal Injection Experience Procedure video viewing - Age Related Macular Degeneration, Diabetic Retinopathy | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 182 | 2025-05-05 | 2025-06-03 |
| An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings With fundus diseases, Without fundus diseases - Retinal Diseases, Choroidal Disease | Not yet recruiting | Zhongshan Ophthalmic Center, Sun Yat-sen University | 9999 | 2025-05-01 | 2025-04-09 |
Showing 20 of 371. Sign in to see all of them.
Choroidal Neovascularization (203) · Macular Degeneration (151) · Polypoidal Choroidal Vasculopathy (50) · Corneal Neovascularization (29) · Retinal Neovascularization (24) · Diabetic Retinopathy (23) · Wet Macular Degeneration (21) · Retinal Diseases (18) · Eye Diseases (15) · Retinal Vein Occlusion (15) · Macular Edema (14) · Retinal Degeneration (12) · Geographic Atrophy (11) · Vision Disorders (10)
Metaplasia (371) · Pathologic Processes (371) · Pathological Conditions, Signs and Symptoms (371) · Eye Diseases (300) · Uveal Diseases (249) · Choroid Diseases (243) · Retinal Diseases (186) · Retinal Degeneration (151) · Cardiovascular Diseases (53) · Vascular Diseases (50) · Choroidal Neovascularization (42) · Endocrine System Diseases (29) · Corneal Diseases (26) · Nervous System Diseases (26)
Ranibizumab (81) · aflibercept (38) · Bevacizumab (34) · Verteporfin (22) · brolucizumab (10) · salicylhydroxamic acid (8) · Intravitreal Injections (7) · Photochemotherapy (6) · Triamcinolone Acetonide (6) · Dexamethasone (5) · faricimab (5) · pazopanib (5) · KH902 fusion protein (4) · Sodium Chloride (4) · E10030 aptamer (3)
Novartis Pharmaceuticals (24) · National Eye Institute (NEI) (15) · Novartis (8) · Medical University of Vienna (7) · Notal Vision Ltd. (7) · Ophthotech Corporation (6) · Chengdu Kanghong Biotech Co., Ltd. (5) · GlaxoSmithKline (5) · Johns Hopkins University (5) · Reza Dana, MD (5) · Singapore National Eye Centre (5) · Sun Yat-sen University (5) · Zhongshan Ophthalmic Center, Sun Yat-sen University (5) · Alcon Research (4) · Allergan (4)
United States (140) · France (31) · Italy (31) · China (30) · South Korea (28) · Germany (21) · Spain (21) · Switzerland (20) · United Kingdom (20) · Israel (17) · Australia (16) · Canada (16) · Brazil (14) · Portugal (13) · Taiwan (13)
Reza Dana, MD, MPH, MSc (4) · Andrii MD Korol, PhD (3) · Ahmad M Mansour, MD (2) · Chong-Lye Ang, FRCOphth (2) · Christian Pruente, MD (2) · David E Newby, MBChB PhD (2) · Dennis M. Marcus, M.D. (2)
PMID 30957581, PMID 30986442, PMID 19427992, PMID 19726427, PMID 22426346, PMID 23084240, PMID 24113783, PMID 32374423, PMID 33207259, PMID 34968756, PMID 37343623, PMID 39033924, PMID 39207600, PMID 11071039, PMID 11297486, PMID 11642370, PMID 11741106, PMID 12707595, PMID 12967792, PMID 14557174, PMID 15013874, PMID 16019682, PMID 16687455, PMID 16765697, PMID 16897221, PMID 17188044, PMID 17404091, PMID 17659962, PMID 17675159, PMID 18046222, PMID 18054887, PMID 18301024, PMID 1850220, PMID 18619571, PMID 18682970, PMID 19029035, PMID 19184312, PMID 19211094, PMID 1922252, PMID 19365012, PMID 19365036, PMID 19376495, PMID 19506188, PMID 19549103, PMID 19592101, PMID 19643495, PMID 19837539, PMID 19936307, PMID 20110127, PMID 20136420
2019 (4), 2009 (2), 2014 (2), 2015 (1), R01EY019112 (1), R01EY033365 (1), R01HL071021 (1), R01HL116226 (1), R44EY018280 (1), U10EY017823 (1)